MedTrace Logo

A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers

NCT07223333 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-02-23

No results posted yet for this study

Summary

The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.

Conditions

Interventions

DRUG

PATAS Trifluoroacetate

A drug targeting the interaction between the ALMS1 protein and alpha-PKC

DRUG

Placebo

Excipient only formulation, without active compound

Sponsors & Collaborators

  • AdipoPharma LLC

    lead INDUSTRY

Principal Investigators

  • Vincent Marion, Ph.D. · AdipoPharma LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-27
Primary Completion
2026-07-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07223333 on ClinicalTrials.gov